X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ONCT

Closed

Oncternal Therapeutics Inc

0.5266
0.0000 (0.00%)
Last Update: 29 Apr 2025 16:30:00
Yesterday: 0.5266
Day's Range: 0.5266 - 0.5266
Send
When Written:
 
0.2752
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company was founded in 1997 and is based in San Diego, California. Oncternal Therapeutics is currently developing a pipeline of products targeting specific cancers, including lymphoma, leukemia, and solid tumors. Its lead product candidate, cirmtuzumab, is a monoclonal antibody that targets the ROR1 protein, which is found on the surface of cancer cells but not on normal cells. The company is also developing TK216, which is a small molecule inhibitor of the ETS family of transcription factors, and ROR1 CAR-T, which is a chimeric antigen receptor T-cell therapy that targets ROR1. Oncternal Therapeutics aims to improve the lives of cancer patients by developing innovative therapies that target the underlying biology of cancer.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
When Written:
 
0.2752
Oncternal Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for the treatment of cancer. The company's lead product candidate, cirmtuzumab, is a monoclonal antibody that targets ROR1, a protein that is expressed on the surface of cancer cells. Oncternal Therapeutics is also developing TK216, a small molecule inhibitor of the ETS family of transcription factors, which are involved in the development of certain types of cancer. The company was founded in 2013 and is headquartered in San Diego, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X